{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:12:22Z","timestamp":1777954342240,"version":"3.51.4"},"reference-count":65,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background\/objectives<\/jats:title>\n                    <jats:p>Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms, and its incidence is steadily increasing. Schizophrenia (SCZ) is a severe psychiatric disorder involving both positive and negative symptoms. Both diseases share dopaminergic dysregulation, but the relationship between schizophrenia and PD and the role of antipsychotic treatment in the risk of PD are not well understood. This study aimed to explore the risk of PD in individuals with schizophrenia and assess the influence of antipsychotic medications on this risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study used a customized database from the National Health Insurance Service (NHIS) of South Korea, which included patients diagnosed with schizophrenia and matched controls. We performed propensity score matching and adjusted for various demographic, clinical, and comorbidity variables. Competing risk analysis and Cox regression were used to analyze the relationship between schizophrenia and PD, considering both antipsychotic medication exposure and comorbid conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that individuals with schizophrenia had a significantly higher risk of developing PD than the control subjects, with an adjusted hazard ratio of 3.198. Among schizophrenia patients, compared with control, risperidone use was associated with an increased risk of PD, whereas quetiapine use was associated with a reduced risk. Significant comorbidities, such as head injury and cerebrovascular disease, also contributed to the increased risk of PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study highlights the elevated risk of PD in individuals with schizophrenia, emphasizing the need for close monitoring of this patient population. The impact of antipsychotic medications, particularly risperidone and quetiapine, on the development of PD warrants further investigation to better understand the long-term effects of these treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0346233","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:50:37Z","timestamp":1777917037000},"page":"e0346233","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of Parkinson\u2019s disease in patients with schizophrenia: Impact of antipsychotic medication use"],"prefix":"10.1371","volume":"21","author":[{"given":"Jin Yeon","family":"Gil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Hyun","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Hyeob","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Hyuk","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Min","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9535-7314","authenticated-orcid":true,"given":"Kyung Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"7","key":"pone.0346233.ref001","article-title":"Temporal trends in the prevalence of Parkinson\u2019s disease from 1980 to 2023: a systematic review and meta-analysis","volume":"5","author":"J Zhu","year":"2024","journal-title":"Lancet Healthy Longev"},{"issue":"9","key":"pone.0346233.ref002","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/jnnp-2015-312283","article-title":"Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis","volume":"87","author":"F Moisan","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"13","key":"pone.0346233.ref003","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"29","author":"T Pringsheim","year":"2014","journal-title":"Mov Disord"},{"key":"pone.0346233.ref004","doi-asserted-by":"crossref","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018","volume-title":"Parkinson\u2019s disease: pathogenesis and clinical aspects. Brisbane (AU)","author":"TB Stoker","year":"2018"},{"issue":"5","key":"pone.0346233.ref005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson\u2019s disease","volume":"20","author":"E Tolosa","year":"2021","journal-title":"Lancet Neurol"},{"issue":"12","key":"pone.0346233.ref006","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson\u2019s disease: risk factors and prevention","volume":"15","author":"A Ascherio","year":"2016","journal-title":"Lancet Neurol"},{"key":"pone.0346233.ref007","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuro.2024.12.003","article-title":"Smoking, coffee intake, and Parkinson\u2019s disease: Potential protective mechanisms and components","volume":"106","author":"SW Hong","year":"2025","journal-title":"Neurotoxicology"},{"issue":"9","key":"pone.0346233.ref008","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.tins.2004.06.008","article-title":"Smoking, nicotine and Parkinson\u2019s disease","volume":"27","author":"M Quik","year":"2004","journal-title":"Trends Neurosci"},{"key":"pone.0346233.ref009","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0166-4328(00)00206-0","article-title":"Smoking and Parkinson\u2019s and Alzheimer\u2019s disease: review of the epidemiological studies","volume":"113","author":"L Fratiglioni","year":"2000","journal-title":"Behav Brain Res"},{"issue":"6","key":"pone.0346233.ref010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/mds.10425","article-title":"Prospective study of phobic anxiety and risk of Parkinson\u2019s disease","volume":"18","author":"MG Weisskopf","year":"2003","journal-title":"Mov Disord"},{"issue":"13","key":"pone.0346233.ref011","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/mds.23230","article-title":"Anxious personality predicts an increased risk of Parkinson\u2019s disease","volume":"25","author":"JH Bower","year":"2010","journal-title":"Mov Disord"},{"issue":"4","key":"pone.0346233.ref012","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/1531-8257(200007)15:4<669::AID-MDS1011>3.0.CO;2-5","article-title":"Anxiety disorders and depressive disorders preceding Parkinson\u2019s disease: a case-control study","volume":"15","author":"M Shiba","year":"2000","journal-title":"Mov Disord"},{"issue":"4","key":"pone.0346233.ref013","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/mds.10387","article-title":"Higher incidence of depression preceding the onset of Parkinson\u2019s disease: a register study","volume":"18","author":"AFG Leentjens","year":"2003","journal-title":"Mov Disord"},{"issue":"10","key":"pone.0346233.ref014","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1212\/WNL.58.10.1501","article-title":"Increased risk of Parkinson\u2019s disease after depression: a retrospective cohort study","volume":"58","author":"AG Schuurman","year":"2002","journal-title":"Neurology"},{"issue":"10039","key":"pone.0346233.ref015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"MJ Owen","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"pone.0346233.ref016","first-page":"1821","article-title":"Schizophrenia: a review","volume":"75","author":"SH Schultz","year":"2007","journal-title":"Am Fam Physician"},{"issue":"9","key":"pone.0346233.ref017","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"KR Patel","year":"2014","journal-title":"P T"},{"issue":"11","key":"pone.0346233.ref018","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/cells8111336","article-title":"Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain","volume":"8","author":"D Grajales","year":"2019","journal-title":"Cells"},{"issue":"1","key":"pone.0346233.ref019","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eurpsy.2004.11.003","article-title":"Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies","volume":"20","author":"A Abi-Dargham","year":"2005","journal-title":"Eur Psychiatry"},{"issue":"9","key":"pone.0346233.ref020","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0706743717720448","article-title":"Guidelines for the Pharmacotherapy of Schizophrenia in Adults","volume":"62","author":"G Remington","year":"2017","journal-title":"Can J Psychiatry"},{"issue":"14","key":"pone.0346233.ref021","doi-asserted-by":"crossref","DOI":"10.12968\/bjon.1998.7.14.5636","article-title":"Role of dopamine in schizophrenia and Parkinson\u2019s disease","volume":"7","author":"J Birtwistle","year":"1998","journal-title":"Br J Nurs"},{"issue":"3","key":"pone.0346233.ref022","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.annepidem.2013.12.010","article-title":"Psychiatric diseases predated the occurrence of Parkinson disease: a retrospective cohort study","volume":"24","author":"H-L Lin","year":"2014","journal-title":"Ann Epidemiol"},{"issue":"8","key":"pone.0346233.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236728","article-title":"The prevalence of psychiatric symptoms before the diagnosis of Parkinson\u2019s disease in a nationwide cohort: A comparison to patients with cerebral infarction","volume":"15","author":"S Szatm\u00e1ri","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"pone.0346233.ref024","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/jamaneurol.2022.3902","article-title":"Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease","volume":"80","author":"A Schrag","year":"2023","journal-title":"JAMA Neurol"},{"issue":"6","key":"pone.0346233.ref025","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.28484","article-title":"Increased Risk of Parkinson\u2019s Disease in Patients With Schizophrenia Spectrum Disorders","volume":"36","author":"T Kuusim\u00e4ki","year":"2021","journal-title":"Mov Disord"},{"key":"pone.0346233.ref026","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejca.2019.04.033","article-title":"Cancer risk in patients with Parkinson\u2019s disease in South Korea: A nationwide, population-based cohort study","volume":"117","author":"J-H Park","year":"2019","journal-title":"Eur J Cancer"},{"issue":"10","key":"pone.0346233.ref027","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1212\/01.WNL.0000068008.78394.2C","article-title":"Head trauma preceding PD: a case-control study","volume":"60","author":"JH Bower","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"pone.0346233.ref028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ana.20882","article-title":"Head injury and Parkinson\u2019s disease risk in twins","volume":"60","author":"SM Goldman","year":"2006","journal-title":"Ann Neurol"},{"issue":"1","key":"pone.0346233.ref029","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/qjmed\/hcu136","article-title":"The association between chronic obstructive pulmonary disease and Parkinson\u2019s disease: a nationwide population-based retrospective cohort study","volume":"108","author":"C-H Li","year":"2015","journal-title":"QJM"},{"issue":"14","key":"pone.0346233.ref030","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.119.044948","article-title":"Association of Parkinson Disease With Risk of Cardiovascular Disease and All-Cause Mortality: A Nationwide, Population-Based Cohort Study","volume":"141","author":"J-H Park","year":"2020","journal-title":"Circulation"},{"key":"pone.0346233.ref031","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.parkreldis.2022.10.012","article-title":"The association of comorbidity with Parkinson\u2019s disease-related hospitalizations","volume":"104","author":"ALAJ Hommel","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"pone.0346233.ref032","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000358921","article-title":"Increased risk of Parkinson\u2019s disease in patients with end-stage renal disease: a retrospective cohort study","volume":"42","author":"I-K Wang","year":"2014","journal-title":"Neuroepidemiology"},{"issue":"3","key":"pone.0346233.ref033","article-title":"Increased risk of Parkinson disease with diabetes mellitus in a population-based study","volume":"96","author":"Y-W Yang","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"pone.0346233.ref034","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.25564","article-title":"Associations between cerebrovascular risk factors and parkinson disease","volume":"86","author":"BR Kummer","year":"2019","journal-title":"Ann Neurol"},{"issue":"5","key":"pone.0346233.ref035","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/08039488.2020.1854853","article-title":"Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences","volume":"75","author":"H Taipale","year":"2021","journal-title":"Nord J Psychiatry"},{"issue":"21","key":"pone.0346233.ref036","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207899","article-title":"Association Between Use of Any of the Drugs Prescribed in Norway and the Subsequent Risk of Parkinson Disease: A Drug-wide Association Study","volume":"101","author":"J Romanowska","year":"2023","journal-title":"Neurology"},{"issue":"446","key":"pone.0346233.ref037","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"JP Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"6","key":"pone.0346233.ref038","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4097\/kjae.2016.69.6.555","article-title":"Alternatives to P value: confidence interval and effect size","volume":"69","author":"DK Lee","year":"2016","journal-title":"Korean J Anesthesiol"},{"issue":"5","key":"pone.0346233.ref039","doi-asserted-by":"crossref","first-page":"349","DOI":"10.14336\/AD.2015.0330","article-title":"Dopamine Receptors and Neurodegeneration","volume":"6","author":"C Rangel-Barajas","year":"2015","journal-title":"Aging Dis"},{"issue":"2","key":"pone.0346233.ref040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00702-019-02120-x","article-title":"The bimodal mechanism of interaction between dopamine and mitochondria as reflected in Parkinson\u2019s disease and in schizophrenia","volume":"127","author":"D Ben-Shachar","year":"2020","journal-title":"J Neural Transm (Vienna)"},{"issue":"11","key":"pone.0346233.ref041","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1007\/s12035-023-03502-9","article-title":"Dissecting the Relationship Between Neuropsychiatric and Neurodegenerative Disorders","volume":"60","author":"R Gupta","year":"2023","journal-title":"Mol Neurobiol"},{"issue":"5","key":"pone.0346233.ref042","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.biopsych.2021.05.025","article-title":"Traumatic Brain Injury and Risk of Neurodegenerative Disorder","volume":"91","author":"BL Brett","year":"2022","journal-title":"Biol Psychiatry"},{"issue":"1","key":"pone.0346233.ref043","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40478-020-00924-7","article-title":"Biological links between traumatic brain injury and Parkinson\u2019s disease","volume":"8","author":"V Delic","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"pone.0346233.ref044","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s11064-021-03503-x","article-title":"Olfactory Bulb Excitotoxicity as a Gap-Filling Mechanism Underlying the Link Between Traumatic Brain Injury-Induced Secondary Neuronal Degeneration and Parkinson\u2019s Disease-Like Pathology","volume":"47","author":"C Marin","year":"2022","journal-title":"Neurochem Res"},{"issue":"1","key":"pone.0346233.ref045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40478-022-01327-6","article-title":"Ischemic stroke causes Parkinson\u2019s disease-like pathology and symptoms in transgenic mice overexpressing alpha-synuclein","volume":"10","author":"S Lohmann","year":"2022","journal-title":"Acta Neuropathol Commun"},{"issue":"9","key":"pone.0346233.ref046","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/ene.12740","article-title":"Risk of Parkinson\u2019s disease following anxiety disorders: a nationwide population-based cohort study","volume":"22","author":"C-H Lin","year":"2015","journal-title":"Eur J Neurol"},{"issue":"9","key":"pone.0346233.ref047","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.parkreldis.2010.06.014","article-title":"Occurrence of depression and anxiety prior to Parkinson\u2019s disease","volume":"16","author":"EL Jacob","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"pone.0346233.ref048","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","article-title":"Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms","volume":"42","author":"RA McCutcheon","year":"2019","journal-title":"Trends Neurosci"},{"issue":"4","key":"pone.0346233.ref049","first-page":"325","article-title":"Quetiapine\u00a0: A Review of its Use in Schizophrenia","volume":"9","author":"NS Gunasekara","year":"1998","journal-title":"CNS Drugs"},{"issue":"4","key":"pone.0346233.ref050","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/00002018-200023040-00003","article-title":"Quetiapine: a review of its safety in the management of schizophrenia","volume":"23","author":"V Dev","year":"2000","journal-title":"Drug Saf"},{"issue":"2","key":"pone.0346233.ref051","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0924-977X(00)00133-4","article-title":"D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study","volume":"11","author":"O Gefvert","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"pone.0346233.ref052","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis","volume":"28","author":"S Siafis","year":"2023","journal-title":"Mol Psychiatry"},{"issue":"4","key":"pone.0346233.ref053","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0893-133X(01)00251-2","article-title":"Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride","volume":"25","author":"J Mukherjee","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"15","key":"pone.0346233.ref054","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1212\/WNL.0b013e31826e25ce","article-title":"Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort","volume":"79","author":"A Foubert-Samier","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"pone.0346233.ref055","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"KD Burris","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"pone.0346233.ref056","doi-asserted-by":"crossref","first-page":"832209","DOI":"10.3389\/fpsyt.2022.832209","article-title":"Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice","volume":"13","author":"XM Hart","year":"2022","journal-title":"Front Psychiatry"},{"issue":"2","key":"pone.0346233.ref057","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5582\/bst.2022.01115","article-title":"Time to onset of drug-induced parkinsonism: Analysis using a large Japanese adverse event self-reporting database","volume":"16","author":"K Sato","year":"2022","journal-title":"Biosci Trends"},{"issue":"1","key":"pone.0346233.ref058","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","article-title":"Drug-induced parkinsonism","volume":"8","author":"H-W Shin","year":"2012","journal-title":"J Clin Neurol"},{"issue":"4","key":"pone.0346233.ref059","doi-asserted-by":"crossref","first-page":"7877","DOI":"10.4081\/ni.2018.7877","article-title":"Clinical features of drug-induced Parkinsonism","volume":"10","author":"N Shiraiwa","year":"2018","journal-title":"Neurol Int"},{"issue":"6","key":"pone.0346233.ref060","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/pds.5007","article-title":"Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults-a propensity score matched cohort study","volume":"29","author":"T-Y Chyou","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"pone.0346233.ref061","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/mds.26209","article-title":"Parkinsonism following neuroleptic exposure: A double-hit hypothesis?","volume":"30","author":"R Erro","year":"2015","journal-title":"Mov Disord"},{"issue":"2","key":"pone.0346233.ref062","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"CU Correll","year":"2022","journal-title":"World Psychiatry"},{"issue":"12","key":"pone.0346233.ref063","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.3390\/healthcare10122366","article-title":"Mortality in Schizophrenia-Spectrum Disorders: Recent Advances in Understanding and Management","volume":"10","author":"V Peritogiannis","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"1","key":"pone.0346233.ref064","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1474-4422(14)70287-X","article-title":"Prediagnostic presentations of Parkinson\u2019s disease in primary care: a case-control study","volume":"14","author":"A Schrag","year":"2015","journal-title":"Lancet Neurol"},{"issue":"7","key":"pone.0346233.ref065","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.26170","article-title":"Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson\u2019s disease","volume":"30","author":"D Weintraub","year":"2015","journal-title":"Mov Disord"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:50:45Z","timestamp":1777917045000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346233"}},"subtitle":[],"editor":[{"given":"Souparno","family":"Mitra","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":65,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0346233","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]}}}